Radoslaw Nowak

• Evaluating the strengths and limitations of phenotypic screening for discovering novel proximity therapeutics
• Comparing biology-first versus chemistry-first approaches to proximity drug discovery
• Leveraging biology-first strategies to unlock non-degrader modalities such as stabilisers, modulators and activators by anchoring discovery in disease-relevant phenotypes and mechanistic pathways
• Addressing the complexity of biological assay readouts in non-oncology indications and discussing how inflammation, neurodegeneration and other areas challenge traditional screening assays

• Showcasing TRAP-1, a novel small molecule that facilitates ternary complex formation between mutant p53 and BRD4, enabling transcriptional reactivation of p53 in oncogenic contexts.
• Demonstrating robust induction of p53 target genes and selective growth inhibition in p53Y220C pancreatic cancer models, underscoring the mechanistic requirement for chemically induced proximity.
• Establishing TCIPs as a promising therapeutic modality to restore tumour suppressor function and address historically intractable transcription factor targets.

Non-Degrader